At 42 days (21 days post‐final treatment, Figure 6J), the tumour volume in the CD38‐EVs‐DoxMNs group was markedly reduced compared to the EVs‐Doxi.v and CD38‐EVs‐Doxi.v groups. The gene discussed is CD38; the disease is neoplasm.